Search
Efzofitimod
go.drugbank.com/drugs/DB16453InvestigationalEfzofitimod (ATYR1923) is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody. … It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states.
XPro1595
go.drugbank.com/drugs/DB16454InvestigationalXPro1595 is an investigational dominant-negative protein that neutralizes soluble TNF.
Synonyms: HOMOSAPIENS TUMOR NECROSIS FACTOR,SOLUBLE FORM (V1>M, R31>C, C69>V, Y87>H, C101>A, A145>R), MONOMER, PEGYLATED ON CYSTEINE 31 : S-((3RS)-(2-((3-(.OMEGA., -METHOXYPOLY(OXYETHANE-1,2-DIYL))PROPYL)CARBAMOYL)ETHYL)-2,5-DIOXOPYRROLIDIN-3-YL)-L-CYSTEINYLHuman Interleukin 8
go.drugbank.com/drugs/DB16456InvestigationalInterleukin-8 is under investigation in clinical trial NCT05148234 (BMS-986253 in Myelodysplastic Syndromes).
TD-0903
go.drugbank.com/drugs/DB16463InvestigationalTD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants
CIGB 300
go.drugbank.com/drugs/DB16464InvestigationalCIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma and adenocarcinoma of the cervix)
Meplazumab
go.drugbank.com/drugs/DB16465InvestigationalMeplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Amubarvimab
go.drugbank.com/drugs/DB16493InvestigationalAmubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.